medigraphic.com
Colegio de Medicina Interna de México.

2019, Number 5

<< Back Next >>

Med Int Mex 2019; 35 (5)

Pemphigus vulgaris

González-Ruiz V, Cordero-Martínez CF, Domínguez-Cherith J, Méndez-Flores S

Language: Spanish
References: 15
Page: 708-712
PDF size: 339.50 Kb.


ABSTRACT

Pemphigus is an autoimmune and chronic disease with low incidence and prevalence. Nevertheless it could reach a 75% mortality rate without treatment. There are two principal types: vulgar pemphigus and foliaceus pemphigus, which are clinically characterized by skin blister appearance, with mucosal affection in patients with pemphigus vulgaris. This review details the epidemiology, etiology, physiopathology and treatment of this disease, remarking the steroid importance as the cornerstone in the management of these patients.


REFERENCES

  1. Huang YH, Kuo CF, Chen YH, Yang YW. Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: a nationwide population-based study. 2012 Jan;132(1):92- 7. doi: 10.1038/jid.2011.249.

  2. Tamgadge S, Tamgadge A, Bhatt DM, Bhalerao S, Pereira T. Pemphigus vulgaris. Contemp Clin Dent 2011;2:134-7. doi: 10.4103/0976-237X.83074.

  3. Kridin K, Sagi SZ, Bergman R. Mortality and cause of death in patients with pemphigus. Acta Derm Venereol 2017 May 8;97(5):607-611. doi: 10.2340/00015555-2611.

  4. DiMarco C. Pemphigus: Pathogenesis to treatment. R I Med J (2013). 2016 Dec 1;99(12):28-31.

  5. Sanders WJ. A brief review of pemphigus vulgaris. Biomedical Dermatology 2017;1:7.

  6. Hanna S, Kim M, Murrell DF. Validation studies of outcome measures in pemphigus. Int J Womens Dermatol 2016;2(4):128-139. doi: 10.1016/j.ijwd.2016.10.003.

  7. Miletta N, Miller ME, Lam T, Chung KK, Hivnor C. The management of pemphigus vulgaris in a burn intensive care unit: a case report and treatment review. J Burn Care Res. 2014 Sep-Oct;35(5):e357-63. doi: 10.1097/ BCR.0000000000000049.

  8. Spindler V, Waschke J. Pemphigus-A disease of desmosome dysfunction caused by multiple mechanisms. Front Immunol 2018 Feb 1;9:136. doi: 10.3389/fimmu.2018.00136.

  9. Harman KE, Brown D, Exton LS, Groves RW, Hampton PJ, Mohd Mustapa MF, Setterfield JF, Yesudian PD. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol 2017 Nov;177(5):1170-1201. doi: 10.1111/bjd.15930.

  10. Mimansa C, Nita C. Management of pemphigus vulgaris. Adv Ther 2016;33:910-958. doi: 10.1007/s12325-016- 0343-4.

  11. Hina H, Pooja K, Vijayta S. A comprehensive review on pemphigus vulgaris. Biomed J Sci & Tech Res 1(6)-2017. DOI:10.26717/BJSTR.2017.01.000552.

  12. Gregoriou S, Efthymiou O, Stefanaki C, Rigopoulos D. Management of pemphigus vulgaris: challenges and solutions. Clin Cosmet Investig Dermatol 2015 Oct 21;8:521-7. doi: 10.2147/CCID.S75908.

  13. Hertl M, Geller S. Initial management of pemphigus vulgaris and pemphigus foliaceus, Up to date. April, 2017. Disponible en: https://www.uptodate.com/contents/initial-management- of-pemphigus-vulgaris-and-pemphigus-foliaceus.

  14. Shahidi-Dadras M, Karami A, Toosy P, Shafiyan A. Pulse versus oral methylprednisolone therapy in pemphigus vulgaris. Arch Iranian Medicine 2007;10(1):1-6. DOI: 07101/AIM.003.

  15. Baican A, et al. Prediction of survival for patients with pemphigus vulgaris and pemphigus foliaceus: a retrospective cohort study. Orphanet J Rare Dis 2015;10:48. doi: 10.1186/ s13023-015-0263-4.




2020     |     www.medigraphic.com